MEDICINE DETAILS
Enspryng
Active ingredient: Satralizumab
Neutral reference profile for an independent medicine-access consultancy enquiry about Enspryng (Satralizumab). No medicine is offered for sale.
NEXT STEP
Choose the strength and pack
✓ If you are unsure, choose “I do not know”.
These options are not medical advice, a dosing recommendation, stock confirmation or a sale offer.
ABOUT THIS MEDICINE
What is Enspryng used for?
Enspryng (satralizumab) is an interleukin-6 (IL-6) receptor antagonist indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adults and children who are anti-aquaporin-4 (AQP4) antibody positive.
It is available in single-dose syringe form containing 120 mg/mL satralizumab.
This information is general and is not medical advice. Talk to your doctor or pharmacist about any treatment decision.
RECORDED PRODUCT PROFILE
Enspryng identity, dosage form and pack information.
The details below are assembled from current catalogue records. They must still be checked against the prescription, medicine box and an official regulatory record.
Recorded strength and pack options
Each row is shown only to help identify the product; it is not stock confirmation or a sale offer.
-
120 mg · 1 pre-filled syringe Catalogue organisation: Roche Pharma AG
-
120 mg · 3 pre-filled syringes Catalogue organisation: Roche Pharma AG
OFFICIAL SOURCES
Check the Enspryng record at an official source.
Search for “Enspryng” or “Satralizumab”. Finding a product in one source does not by itself confirm stock, authorisation in a particular country or suitability for a patient.
OFFICIAL EXTERNAL SOURCE
European Medicines Agency (EMA)
Search medicines evaluated by EMA by brand name or active substance. EMA also links to national registers for nationally authorised products.
↗ OFFICIAL EXTERNAL SOURCE Drugs@FDASearch FDA-approved human drug records by brand name or active ingredient, including current labelling where available.
↗SERVICE BOUNDARY
Information checking and independent enquiry support for Enspryng.
OrphanDrug helps organise the product identity and recorded strength and pack details for an enquiry. It does not sell, take payment for, prescribe, import, dispense or deliver medicines.
Clinical decision: Only a qualified healthcare professional who has assessed the patient can decide whether a product, form or dose is appropriate.
CLEAR ANSWERS
Frequently asked questions about Enspryng
01What is Enspryng?＋
This directory record associates the brand name Enspryng with the active ingredient Satralizumab. The brand and ingredient are shown for product identification only, not as treatment or dosing advice.
02Which Enspryng strengths and packs are recorded?＋
The catalogue currently shows: 120 mg · 1 pre-filled syringe; 120 mg · 3 pre-filled syringes. Check the complete strength, dosage form and pack description against the prescription and medicine box.
03Who manufactures Enspryng?＋
Catalogue records currently name: Roche Pharma AG. This field may identify a manufacturer, marketing-authorisation holder, marketing company or supplier; confirm the exact role on the pack leaflet and official regulatory record.
04Do the listed options confirm stock or access?＋
No. A catalogue record does not confirm current stock, authorisation in a particular country, clinical suitability, import permission or access.
05What affects a possible estimated medicine cost for Enspryng?＋
A possible cost depends on the exact strength, dosage form, pack, quantity, destination and regulatory jurisdiction. Any amount provided after an enquiry is an indicative medicine-cost estimate only, not a selling price for Enspryng, payment request, stock guarantee or binding offer.
06Can I buy Enspryng from this website?＋
No. This website does not sell, take payment for, prescribe, import, dispense or deliver medicines. The form creates an independent consultancy enquiry only.